Philip Liebson to Follow-Up Studies
This is a "connection" page, showing publications Philip Liebson has written about Follow-Up Studies.
Connection Strength
0.186
-
Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET): implications for reduced cardiovascular risk. Prev Cardiol. 2009; 12(1):43-50.
Score: 0.057
-
ALLHAT and AFFIRM. Prev Cardiol. 2003; 6(1):54-60.
Score: 0.038
-
Relationships of quality-of-life measures to long-term lifestyle and drug treatment in the Treatment of Mild Hypertension Study. Arch Intern Med. 1997 Mar 24; 157(6):638-48.
Score: 0.025
-
Effect of left atrial size on recurrence of atrial fibrillation after electrical cardioversion: atrial dimension versus volume. Am J Card Imaging. 1996 Oct; 10(4):261-5.
Score: 0.024
-
Clinical correlates and prognostic significance of change in standardized left ventricular mass in a community-based cohort of African Americans. J Am Heart Assoc. 2015 Feb 05; 4(2).
Score: 0.022
-
Optimal threshold value for left ventricular hypertrophy in blacks: the Atherosclerosis Risk in Communities study. Hypertension. 2005 Jan; 45(1):58-63.
Score: 0.011
-
Smoking cessation and arrhythmic death: the CAST experience. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. J Am Coll Cardiol. 1995 Nov 01; 26(5):1287-92.
Score: 0.006
-
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991 Mar 21; 324(12):781-8.
Score: 0.004